Trials / Completed
CompletedNCT02545439
A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers
A Phase 1 Study to Evaluate the Impact of CYP3A4 Induction on the Single Dose Pharmacokinetics of ALKS 5461
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the impact of CYP3A4 induction on the single-dose pharmacokinetics of ALKS 5461.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 5461 | Sublingual tablet given alone and in conjunction with Rifampin |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2015-09-10
- Last updated
- 2015-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02545439. Inclusion in this directory is not an endorsement.